// Biotech and Pharma Therapeutics
Eli Lilly adds high-dose Zepbound options to lineup of cheaper vials available on self-pay website
June 16, 2025 / Zepbound pricing update / Eli Lilly obesity drug / high-dose GLP-1 access / self-pay weight loss medication / obesity treatment affordability
Eli Lilly is expanding access to its obesity drug Zepbound by adding high-dose options (12.5 mg and 15 mg) to its $499/month self-pay program, aiming to improve affordability amid limited insurance coverage for chronic obesity treatments.
CDC workers fired from prominent STI, hepatitis labs are rehired
June 16, 2025 / CDC workers fired from prominent STI, hepatitis labs are rehiredCDC workers fired from prominent STI, hepatitis labs are rehired
The CDC has reversed planned layoffs of 55 staff from its leading STI and viral hepatitis labs, preserving critical public health infrastructure after previously announced terminations linked to broader federal budget cuts.
The Benefits of Reshoring Medical Device Manufacturing
June 17, 2025 / Medical device reshoring / ISO 13485 manufacturing / FDA compliance supply chain / intellectual property protection / rapid medical device production
Reshoring medical device manufacturing enhances quality, regulatory compliance, IP protection, and speed-to-market. U.S.-based partners like BCI offer ISO 13485-certified production, rapid turnaround, and tighter collaboration, addressing challenges from offshore supply chains and supporting innovation in a regulated environment.
When Innovation Outpaces Adoption, Patients Pay the Price
June 17, 2025 / Robotic surgery adoption / Endovascular robotics innovation / Healthcare technology barriers / Cardiac ablation robotics / Patient safety surgical robotics
Despite proven benefits in precision and safety, robotic-assisted systems remain underutilized in endovascular procedures due to outdated perceptions and systemic barriers. Bridging this innovation-adoption gap is essential to improve outcomes, reduce complications, and advance patient care.
How Wearables Are Changing the Way We Monitor Cancer Treatment
June 17, 2025 / Cancer monitoring / Remote wearables / Chemotherapy safety / Neutropenic fever detection
Wearable devices for remote patient monitoring are transforming cancer care by enabling early detection of complications like neutropenic fever and cytokine release syndrome, improving outcomes, reducing hospitalizations, and allowing safer outpatient chemotherapy and immunotherapy management through real-time physiological tracking.
// 4th Industrial Revolution
SS Innovations’ robot used in its first cardiac surgery in Americas
June 17, 2025 / Robotic surgery / Cardiac robotics / Minimally invasive cardiology / SSi Mantra system / SS Innovations
SS Innovations’ SSi Mantra 3 robotic system was used for the first time in the Americas to perform a successful robotic cardiac procedure, marking a key milestone in accessible, minimally invasive cardiovascular surgery and global surgical robotics adoption.
Aussie AI scribe startup to go global with $12M funding
June 17, 2025 / AI clinical scribe / Medical documentation AI / Lyrebird Health funding / EMR integration / Healthcare AI startup
Lyrebird Health, an Australian startup developing AI-powered clinical documentation tools, raised $12M to expand globally. Its AI scribe, integrated into leading EMRs, enhances documentation efficiency and accuracy, with upcoming deployments in the UK and Middle East healthcare systems.
Singaporean doctors develop agentic AI-powered scribe
June 16, 2025 / AI clinical assistant / Agentic AI scribe / Healthcare documentation AI / Singapore health tech / Clinical workflow automation
Singapore’s AIGP Health has developed Anzu, an agentic AI-powered clinical assistant that autonomously supports history taking, triage, and follow-up. It improves documentation accuracy, reduces clinician burden by up to 40%, and integrates seamlessly into diverse care settings.
3 points to ponder before tapping AI for mental healthcare
June 16, 2025 / AI mental health / Therabot chatbot therapy / Digital therapeutics AI / Clinical AI responsibility / Long-term AI outcomes
Early trials of the AI chatbot Therabot show promise for mental health support, but experts urge caution, emphasizing the need for rigorous evidence, long-term impact evaluation, and defined legal and clinical responsibility in AI-driven mental healthcare.
New device uses single drop of blood to assess newborn immune health
June 17, 2025 / neonatal immune profiling / newborn sepsis detection / microfluidic diagnostic device / point-of-care neonatal testing / BLIPI infant immune health
A new microfluidic device, BLIPI, enables rapid immune profiling of newborns using just one blood drop. It offers real-time detection of life-threatening conditions like sepsis and NEC, improving early intervention in neonatal intensive care and low-resource settings.
// Business & Markets
Lilly to acquire Verve in $1B bet on gene editing for heart disease
June 17, 2025 / digital health payments / patient billing automation / healthcare revenue cycle / online patient payments / EHR integration
Eli Lilly will acquire Verve Therapeutics for $1B, expanding its gene editing capabilities for cardiovascular disease. The deal centers on Verve’s one-time therapy VERVE-102, aiming to replace chronic care with durable, single-administration genetic treatment.
CDC Scientist Resigns in Protest as Kennedy Reshapes Vaccine Regulation
June 17, 2025 / vaccine policy controversy / CDC scientist resignation / Robert F. Kennedy Jr. HHS / ACIP panel overhaul / U.S. vaccine regulation
CDC scientist Fiona Havers resigned in protest over HHS Secretary Robert F. Kennedy Jr.’s overhaul of vaccine policy and the ACIP panel, citing concerns about diminished scientific rigor and political interference in U.S. vaccine decision-making processes.
Medtech CDMO VitalPath names permanent CFO
June 17, 2025 / VitalPath CFO appointment / catheter manufacturing CDMO / medtech financial leadership / Aimee Moore VitalPath / medical device industry news
VitalPath, a medtech CDMO specializing in complex catheter manufacturing, has appointed Aimee Moore as permanent CFO. Moore brings nearly three decades of financial leadership to support the company’s strategic growth and commitment to improving patient outcomes.
Sword Health Raises $40M, Launches AI-Powered Mental Health Solution “Mind”
June 17, 2025 / AI mental health care / Sword Health funding / digital behavioral health / continuous therapy innovation / wearable mental health tech
Sword Health raised $40M to launch Mind, an AI-powered mental health platform integrating real-time monitoring, AI-driven therapy, and Ph.D.-level clinicians to deliver continuous, personalized care—shifting mental health treatment from episodic sessions to proactive, 24/7 support.
HOPPR Secures $31.5M to Scale its AI Medical Imaging Development Platform
June 17, 2025 / AI medical imaging / HOPPR Series A funding / clinical imaging AI / foundation model development / healthcare AI platform
HOPPR raised $31.5M to expand its AI imaging development platform, enabling secure, compliant fine-tuning of foundation models for clinical use. The platform supports medical imaging developers with traceable workflows, trusted datasets, and tools for rapid model validation and deployment.
// Legal & Regulatory
FDA launches new priority review voucher program for biopharmas that ‘align with national priorities’
June 17, 2025 / FDA priority voucher / accelerated drug approval / CNPV program / U.S. health priorities / biopharma regulation
The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program to accelerate drug approvals to 1–2 months for biopharmas addressing critical U.S. health priorities, encouraging early submission of key materials and leveraging team-based, expedited review processes.
Ibtrozi Wins FDA Approval for ROS1+ NSCLC, Set to Challenge Reigning TKIs Xalkori, Augtyro and Rozlytrek
June 17, 2025 / ROS1 NSCLC / taletrectinib approval / Ibtrozi lung cancer / FDA oncology approval / brain metastases treatment
The FDA has approved Ibtrozi (taletrectinib) for ROS1-positive advanced NSCLC, offering strong intracranial efficacy and a favorable safety profile. This next-gen TKI may challenge existing therapies like Xalkori, Augtyro, and Rozlytrek in a competitive lung cancer market.
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
June 17, 2025 / OCU410ST gene therapy / Stargardt disease treatment / Ocugen FDA approval / retinal degeneration trial / ABCA4-associated retinopathy
The FDA cleared Ocugen’s IND amendment to begin a Phase II/III trial of OCU410ST, a gene therapy for Stargardt disease. The trial will assess lesion size reduction and visual acuity improvements in patients with ABCA4-associated retinal degeneration.
With FDA nod for HAE drug Andembry, CSL set to compete with Takeda’s Takhzyro
June 17, 2025 / Andembry FDA approval / hereditary angioedema treatment / CSL HAE therapy / factor XIIa inhibitor / HAE prophylactic drug
CSL’s Andembry has received FDA approval as a prophylactic treatment for hereditary angioedema (HAE), targeting factor XIIa. The monoclonal antibody offers monthly self-administration and demonstrated significant reduction in HAE attacks, positioning CSL to challenge Takeda and BioCryst.
FDA approves UroGen’s Zusduri to treat recurrent bladder cancer
June 17, 2025 / FDA bladder cancer approval / Zusduri mitomycin treatment / non-muscle invasive bladder cancer / UroGen LG-IR-NMIBC therapy / outpatient bladder cancer drug
The FDA has approved UroGen’s Zusduri (mitomycin intravesical solution) as the first drug for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), offering a non-surgical outpatient alternative to TURBT with strong clinical response and durability.
// Research & Development
More accurate ageing clock relies only on clinical data
June 17, 2025 / biological ageing clock / clinical ageing model / LinAge2 healthspan tool / ageing prediction algorithm / personalised ageing care
Singaporean researchers have developed LinAge2, a clinical data-based biological ageing clock that outperforms DNA-based models in predicting mortality and functional decline, offering physicians a practical, personalized tool to assess ageing and guide interventions for healthier, longer lives.
Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug
June 16, 2025 / Parkinson’s disease treatment / prasinezumab Phase 3 trial / alpha-synuclein antibody / disease-modifying Parkinson’s drug / Roche Prothena partnership
Despite missing primary endpoints in two mid-stage trials, Roche is advancing prasinezumab into Phase 3 for early Parkinson’s disease, citing delayed symptom progression and potential disease-modifying effects targeting alpha-synuclein in continued analyses and open-label extensions.
On heels of Metsera, Lilly delivers more momentum for amylin in obesity
June 16, 2025 / amylin receptor agonist / eloralintide obesity trial / Eli Lilly weight loss drug / ADA 2025 data / amylin monotherapy efficacy
Eli Lilly’s Phase I data on eloralintide, a novel amylin receptor agonist, show strong weight loss efficacy and a favorable safety profile, reinforcing amylin’s emerging potential as a promising obesity treatment target following recent industry momentum.
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
June 17, 2025 / reproxalap / dry eye disease treatment / Aldeyra NDA resubmission / FDA ophthalmology drug / ocular inflammation therapy
Aldeyra Therapeutics has resubmitted its NDA for reproxalap, a topical treatment for dry eye disease, following successful Phase 3 results that addressed FDA concerns. The trial met its primary endpoint with no major safety issues reported.
City of Hope study targets custom-built cancer therapies
June 17, 2025 / glioma research / extrachromosomal DNA / tumor microenvironment insights / precision oncology therapies / City of Hope cancer study
City of Hope researchers identified how extrachromosomal DNA (ecDNA) drives glioma development and alters the tumor microenvironment, advancing precision oncology through insights into genetic instability, hypoxia, and oncogene activity that may guide more effective, personalized cancer treatments.
// Politics
Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others
June 17, 2025 / pharma tax avoidance / offshore pharma profits / Pfizer tax controversy / drug pricing legislation / Big Pharma lobbying
U.S. lawmakers have reignited scrutiny on major pharma companies, including Pfizer and AbbVie, for allegedly avoiding billions in federal taxes by shifting profits offshore—raising concerns about funding gaps for Medicare, Medicaid, and access to affordable prescription drugs.
Medicaid cuts could result in more than 16,000 preventable deaths annually
June 16, 2025 / Medicaid cuts impact / preventable deaths Medicaid / ACA reform consequences / uninsured Americans 2025 / healthcare policy analysis
Proposed Medicaid cuts in the “One Big Beautiful Bill Act” could cause over 16,000 preventable deaths annually and 7.6 million insurance losses, highlighting the serious health consequences of limiting public health coverage, according to Annals of Internal Medicine.
Lawmakers draft VA oversight plan for Oracle Health EHR implementation
June 16, 2025 / Oracle EHR implementation / VA health record modernization / electronic health record safety / veteran healthcare oversight / clinical workflow standardization
Lawmakers have proposed enhanced oversight for the VA’s Oracle Health EHR rollout to address past safety, cost, and training issues. The plan includes standardized workflows, quality metrics, and data privacy protections to ensure consistent, high-quality care across VA facilities.
In setback for biopharma, Senate version of Trump’s tax bill drops Orphan Cures Act
June 17, 2025 / Orphan Cures Act / rare disease drug policy / Medicare drug pricing / Inflation Reduction Act / biopharma R&D incentives
The Senate dropped the Orphan Cures Act from its tax bill, a setback for biopharma seeking exemptions from Medicare drug price negotiations under the IRA—potentially discouraging follow-on rare disease drug development and impacting investment in post-approval trials.
Purdue Pharma $7.4 billion opioid settlement wins broad support from US states
June 16, 2025 / opioid crisis settlement / Purdue Pharma bankruptcy / Sackler family OxyContin / opioid epidemic lawsuits / addiction recovery funding
Purdue Pharma’s $7.4 billion opioid settlement, backed by 55 U.S. states and territories, aims to resolve lawsuits over OxyContin’s role in the opioid crisis. Funds will support addiction recovery efforts, while the Sacklers relinquish company control.